Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2003-02-24
2004-11-09
Metzmaier, Daniel S. (Department: 1712)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C264S004300, C264S004600, C424S450000, C436S829000, C514S055000, C514S851000
Reexamination Certificate
active
06815432
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to formulations for therapeutic nucleic acid delivery and methods for their preparation, and in particular to lipid encapsulated plasmids or antisense constructs. The invention provides a circulation-stable, characterizable delivery vehicle for the introduction of plasmids or antisense compounds into cells. These vehicles are safe, stable, and practical for clinical use.
BACKGROUND OF THE INVENTION
Gene therapy is an area of current interest which involves the introduction of genetic material into a cell to facilitate expression of a deficient protein. There are currently five major methods by which this is accomplished, namely: (i) calcium phosphate precipitation, (ii) DEAE-dextran complexes, (iii) electroporation, (iv) cationic lipid complexes and (v) reconstituted viruses or virosomes (see Chang, et al.,
Focus
10:88 (1988)). Cationic lipid complexes are presently the most effective generally used means of effecting transfection.
A number of different formulations incorporating cationic lipids are commercially available, namely (i) LIPOFECTIN® (which uses 1,2-dioleyloxy-3-(N,N,N-trimethyfamino)propane chloride, or DOTMA, see Eppstein, et al., U.S. Pat. No. 4,897,355); LIPOFECTAMINE® (which uses DOSPA, see Hawley-Nelson, et al.,
Focus
15(3):73 (1993)); and LIPOFECTACE® (which uses N,N-distearyl-N,N-dimethylammonium bromide, or DDAB, see Rose, U.S. Pat. No. 5,279,833). Others have reported alternative cationic lipids that work in essentially the same manner but with different efficiencies, for example 1,2-dioleoyloxy-3-(N,N,N-trimethylamino)propane chloride, or DOTAP, see Stomatatos, et al.,
Biochemistry
27:3917-3925 (1988)); glycerol based lipids (see Leventis, et al.,
Biochem. Biophys. Acta
1023:124 (1990); lipopolyamines (see, Behr, et al., U.S. Pat. No. 5,171,678) and cholesterol based lipids (see Epand, et al., WO 93/05162, and U.S. Pat. No. 5,283,185).
Others have noted that DOTMA and related compounds are significantly more active in transfection assays than their saturated analogues (see, Felgner, et al., WO91/16024). However, both DOTMA and DOSPA based formulations, despite being the most efficient of the cationic lipids in effecting transfection, are prohibitively expensive. DDAB on the other hand is inexpensive and readily available from chemical suppliers but is less effective than DOTMA in most cell lines. Another disadvantage of the current lipid systems is that they are not appropriate for intravenous injection.
An examination of the relationship between the chemical structure of the carrier vehicle and its efficiency of transfection has indicated that the characteristics which provide for effective transfection would make a carrier unstable in circulation (see, Ballas, et al.,
Biochim. Biophys. Acta
939:8-18 (1988)). Additionally, degradation either outside or inside the target cell remains a problem (see, Duzghines,
Subcellular Biochemistry
11:195-286 (1985)). Others who have attempted to encapsulate DNA (Szoka et al.,
Ann. Rev. Biophys. Bioeng.
9:467 (1980); and Deamer, U.S. Pat. No. 4,515,736) made no efforts to ensure a safe, injectable formulation, or arrived at inefficient loading (Legendre,
Pharm. Res.
9:1235-1242 (1992)).
Ideally, a delivery vehicle for a nucleic acid or plasmid will have the following characteristics: a) small enough and long lived enough to distribute from local injection sites when given intravenously, b) capable of carrying a large amount of DNA per particle to enable transfection of all sizes of genes and reduce the volume of injection, c) homogenous, d) reproducible, e) protective of DNA from extracellular degradation and f) capable of transfecting target cells in such a way that the DNA is not digested intracellularly.
The present invention provides such compositions and methods for their preparation and use.
SUMMARY OF THE INVENTION
In one aspect, the present invention provides methods for the preparation of serum-stable plasmid-lipid particles. In one group of these methods, a plasmid is combined with cationic lipids in a detergent solution to provide a coated plasmid-lipid complex. The complex is then contacted with non-cationic lipids to provide a solution of detergent, a plasmid-lipid complex and non-cationic lipids, and the detergent is then removed to provide a solution of serum-stable plasmid-lipid particles, in which the plasmid is encapsulated in a lipid bilayer. The particles, thus formed, have a size of about 50-150 nm.
In a related group of methods the serum-stable plasmid-lipid particles are formed by preparing a mixture of cationic lipids and non-cationic lipids in an organic solvent; contacting an aqueous solution of plasmid with the mixture of cationic and non-cationic lipids to provide a clear single phase; and removing the organic solvent to provide a suspension of plasmid-lipid particles, in which the plasmid is encapsulated in a lipid bilayer, and the particles are stable in serum and have a size of about 50-150 nm.
In another aspect, the present invention provides plasmid-lipid particles prepared by the above methods.
In yet another aspect, the present invention provides methods of transfecting cells using these plasmid-lipid particles.
REFERENCES:
patent: 4394448 (1983-07-01), Szoka, Jr. et al.
patent: 4438052 (1984-03-01), Weder et al.
patent: 4515736 (1985-05-01), Deamer
patent: 4598051 (1986-07-01), Papahadjopoulos et al.
patent: 4897355 (1990-01-01), Eppstein et al.
patent: 5171678 (1992-12-01), Behr et al.
patent: 5208036 (1993-05-01), Eppstein et al.
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5279833 (1994-01-01), Rose
patent: 5283185 (1994-02-01), Epand et al.
patent: 5320906 (1994-06-01), Eley et al.
patent: 5545412 (1996-08-01), Eppstein et al.
patent: 5976567 (1999-11-01), Wheeler et al.
patent: 5981501 (1999-11-01), Wheeler et al.
patent: 6534484 (2003-03-01), Wheeler et al.
patent: 6586410 (2003-07-01), Wheeler et al.
patent: WO 91/16024 (1991-10-01), None
patent: WO 93/05162 (1993-03-01), None
patent: WO 93/12756 (1993-07-01), None
patent: WO 95/02698 (1995-01-01), None
patent: WO 96/10390 (1996-04-01), None
Ballas, et al.,Biochim. Biophys. Acta, 939:8-18 (1988).
Barinaga,Science, 266:1326 (1994).
Brigham, et al.,Am. J. Med. Sci., 298:278-281 (1989).
Crystal,Science, 270:404-410 (1995).
Duzgunes,Subcellular Biochemistry, 11:195-286 (1985).
Gao, et al.,Biochem. Biophys. Res. Comm., 179:280-285 (1991).
Hawley-Nelson, et al.,Focus, 15(3):73 (1993).
Hyde, et al.,Nature, 362:250-256 (1993).
Juliano,Biochem. Biophys. Res. Commun., 63:651-658 (1975).
Legendre,Pharm. Res., 9:1235-1242 (1992).
Leventis, et al.,Biochem. Biophys. Acta, 1023:124 (1990).
Marshall,Science, 269:1050-1055 (1995).
Orkin, et al.,NIH Report, Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy(1995).
Puyal, et al.,Eur. J. Biochem., 228:697-703 (1995).
Stamatatos, et al.,Biochemistry, 27:3917-3925 (1988).
Szoka, et al.,Ann. Rev. Biophys. Bioeng., 9:467-508 (1980).
Woodle, et al.,Biochim. Biophys. Acta, 1105:193-200 (1992).
Zhu, et al.,Science, 261:209-211 (1993).
Bally Marcel B.
Cullis Pieter R.
Hope Michael
Wheeler Jeffery J.
Inex Pharmaceuticals Corp.
Metzmaier Daniel S.
Townsend and Townsend / and Crew LLP
LandOfFree
Methods for encapsulating plasmids in lipid bilayers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for encapsulating plasmids in lipid bilayers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for encapsulating plasmids in lipid bilayers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3355720